InVitro International (IVRO)
USD 0.1
(15.93%)
USD 0.1
(15.93%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 792.62 Thousand USD | -7.13% |
| 2022 | 853.51 Thousand USD | -14.94% |
| 2021 | 1 Million USD | -9.18% |
| 2020 | 1.1 Million USD | 4.95% |
| 2019 | 1.05 Million USD | 24.39% |
| 2018 | 846.33 Thousand USD | -1.08% |
| 2017 | 855.61 Thousand USD | -3.24% |
| 2016 | 884.24 Thousand USD | -11.11% |
| 2015 | 994.71 Thousand USD | 44.98% |
| 2014 | 686.11 Thousand USD | 0.0% |
| 1996 | 1.1 Million USD | 0.0% |
| 1995 | 1.1 Million USD | -35.29% |
| 1994 | 1.7 Million USD | -10.53% |
| 1993 | 1.9 Million USD | 35.71% |
| 1992 | 1.4 Million USD | 180.0% |
| 1991 | 500 Thousand USD | -61.54% |
| 1990 | 1.3 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 211.62 Thousand USD | 14.74% |
| 2024 Q2 | 210.61 Thousand USD | -0.48% |
| 2024 Q3 | 167.85 Thousand USD | -20.3% |
| 2023 Q2 | 199.09 Thousand USD | -4.86% |
| 2023 Q4 | 184.43 Thousand USD | -7.72% |
| 2023 Q1 | 209.25 Thousand USD | 22.0% |
| 2023 Q3 | 199.85 Thousand USD | 0.38% |
| 2023 FY | 792.62 Thousand USD | -7.13% |
| 2022 Q3 | 238.21 Thousand USD | -8.46% |
| 2022 FY | 853.51 Thousand USD | -14.94% |
| 2022 Q1 | 183.56 Thousand USD | -35.89% |
| 2022 Q2 | 260.22 Thousand USD | 41.76% |
| 2022 Q4 | 171.52 Thousand USD | -28.0% |
| 2021 Q2 | 205.11 Thousand USD | 0.0% |
| 2021 FY | 1 Million USD | -9.18% |
| 2021 Q4 | 286.32 Thousand USD | -7.85% |
| 2021 Q3 | 310.71 Thousand USD | 51.48% |
| 2020 FY | 1.1 Million USD | 4.95% |
| 2019 FY | 1.05 Million USD | 24.39% |
| 2018 FY | 846.33 Thousand USD | -1.08% |
| 2017 FY | 855.61 Thousand USD | -3.24% |
| 2016 FY | 884.24 Thousand USD | -11.11% |
| 2015 FY | 994.71 Thousand USD | 44.98% |
| 2014 FY | 686.11 Thousand USD | 0.0% |
| 1997 Q2 | 164 Thousand USD | -45.33% |
| 1997 Q3 | 181 Thousand USD | 10.37% |
| 1997 Q1 | 300 Thousand USD | 0.0% |
| 1996 Q3 | 300 Thousand USD | 0.0% |
| 1996 Q4 | 300 Thousand USD | 0.0% |
| 1996 Q1 | 200 Thousand USD | -33.33% |
| 1996 Q2 | 300 Thousand USD | 50.0% |
| 1996 FY | 1.1 Million USD | 0.0% |
| 1995 Q2 | 200 Thousand USD | -33.33% |
| 1995 FY | 1.1 Million USD | -35.29% |
| 1995 Q4 | 300 Thousand USD | 0.0% |
| 1995 Q3 | 300 Thousand USD | 50.0% |
| 1995 Q1 | 300 Thousand USD | -40.0% |
| 1994 Q4 | 500 Thousand USD | 66.67% |
| 1994 Q1 | 600 Thousand USD | -14.29% |
| 1994 Q2 | 300 Thousand USD | -50.0% |
| 1994 Q3 | 300 Thousand USD | 0.0% |
| 1994 FY | 1.7 Million USD | -10.53% |
| 1993 Q1 | 300 Thousand USD | 0.0% |
| 1993 Q3 | 500 Thousand USD | 66.67% |
| 1993 Q4 | 700 Thousand USD | 40.0% |
| 1993 FY | 1.9 Million USD | 35.71% |
| 1993 Q2 | 300 Thousand USD | 0.0% |
| 1992 Q2 | 500 Thousand USD | 150.0% |
| 1992 FY | 1.4 Million USD | 180.0% |
| 1992 Q4 | 300 Thousand USD | -25.0% |
| 1992 Q3 | 400 Thousand USD | -20.0% |
| 1992 Q1 | 200 Thousand USD | -33.33% |
| 1991 Q3 | 300 Thousand USD | -25.0% |
| 1991 FY | 500 Thousand USD | -61.54% |
| 1991 Q4 | 300 Thousand USD | 0.0% |
| 1991 Q2 | 400 Thousand USD | 33.33% |
| 1991 Q1 | 300 Thousand USD | 0.0% |
| 1990 Q2 | 200 Thousand USD | 100.0% |
| 1990 FY | 1.3 Million USD | 0.0% |
| 1990 Q1 | 100 Thousand USD | 0.0% |
| 1990 Q3 | 300 Thousand USD | 50.0% |
| 1990 Q4 | 300 Thousand USD | 0.0% |
| 1989 Q3 | 100 Thousand USD | 0.0% |
| 1989 Q4 | 100 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | 13.184% |
| Arrayit Corporation | 4.37 Million USD | 81.892% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | 96.935% |
| Bioqual, Inc. | 58.59 Million USD | 98.647% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | 94.818% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 99.989% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | 87.549% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | 24.626% |
| Interpace Biosciences, Inc. | 40.21 Million USD | 98.029% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -77.124% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | 92.879% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | 89.028% |
| NovelStem International Corp. | 12 Thousand USD | -6505.233% |
| Optigenex Inc. | 465.97 Thousand USD | -70.103% |
| PharmChem, Inc. | 6.01 Million USD | 86.817% |
| Proteome Sciences plc | 6.4 Million USD | 87.616% |
| Response Genetics, Inc | 18.04 Million USD | 95.606% |
| Rennova Health, Inc. | 13.03 Million USD | 93.92% |
| RushNet, Inc. | 1.78 Million USD | 55.667% |
| ScreenPro Security Inc. | 1.91 Million USD | 58.59% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | 79.114% |
| Todos Medical Ltd. | 7.69 Million USD | 89.699% |